National Cancer Institute, Ministry of Health, Kyiv, Ukraine.
Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine.
J Med Life. 2023 Jan;16(1):153-159. doi: 10.25122/jml-2022-0172.
Expression of pro-malignant factors (VEGF) and cytokines like inflammatory components support breast cancer development. We examined 46 patients with stage IIIB inflammatory breast cancer (IBC) and 24 with stage IIA-IIIB breast cancer (BC) without secondary edema. Hormone receptors, Her-2/neu, Ki-67 index, VEGF, and IL-6, were determined for all patients before and after neoadjuvant treatment. They associated the expression of VEGF for IBC patients with an unfavorable prognosis. VEGF level for IBC lymph node metastases was higher than in patients without such lesions (1.4 times), and there was a significant increase in VEGF levels in the G3 category of malignancy (1.54-fold increase). In IBC patients with positive HER2/neu status, VEGF levels were 1.51 times higher compared to those with negative HER2/neu status (r=0.36, p<0.05). IL-6 level during therapy in IBC patients remained high, which occurs in active tumor development. Comparative analysis of the VEGF/IL-6 ratio during treatment of patients with IBC was higher . IIIB stage breast cancer without edema (1.4 . 0.7), indicating the aggressiveness of the tumor process and confirmed by an objective response to treatment (regression<30%).
促癌因子（VEGF）和细胞因子等炎症成分的表达支持乳腺癌的发展。我们检查了 46 例 IIIB 期炎性乳腺癌（IBC）患者和 24 例无继发性水肿的 IIA-IIIB 期乳腺癌（BC）患者。所有患者在新辅助治疗前后均测定了激素受体、Her-2/neu、Ki-67 指数、VEGF 和 IL-6。他们将 IBC 患者的 VEGF 表达与不良预后相关联。IBC 淋巴结转移患者的 VEGF 水平高于无此类病变的患者（高 1.4 倍），恶性程度 G3 类别的 VEGF 水平显著升高（增加 1.54 倍）。在 HER2/neu 阳性的 IBC 患者中，VEGF 水平比 HER2/neu 阴性的患者高 1.51 倍（r=0.36，p<0.05）。IBC 患者治疗期间的 IL-6 水平仍然很高，这发生在肿瘤的活跃发展过程中。对 IBC 患者治疗期间 VEGF/IL-6 比值的比较分析显示比值较高。无水肿的 IIIB 期乳腺癌（1.4:0.7），表明肿瘤过程的侵袭性，并通过对治疗的客观反应得到证实（消退<30%）。
